Stanford, Fatima Cody http://orcid.org/0000-0003-4616-533X
Article History
First Online: 13 December 2023
Change Date: 16 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41575-024-00908-1
Competing interests
: F.C.S. has served as a paid advisor/consultant to Caibrate, GoodRx, Pfizer, Eli Lilly, Boehringer Ingelheim, Gelesis, Vida Health, Life Force, Ilant Health, Melli Cell, Novo Nordisk, Clearmind Medicine, and Sweetch.